Detail Article

METOCLOPRAMIDE AND RISK OF TARDIVE DYSKINESIA

POSTING : 17 February 2015

Metoclopramide is a dopamine receptor antagonist approved marketing in Indonesia with an indication of diabetic gastroparesis, nausea, vomiting and reflux esophagitis. More recently, showing a new or current information related to drug safety aspects of metoclopramide that reported by the US FDA and then also published in WHO News Letter. Mentioned in the publication that these drugs cause tardive dyskinesia risk in long-term use (chronic) or high doses, especially in elderly female patients....Read more


Previous Back Next



Loadingss